Qiagen backs EQT's €10.8 billion take-private, six years after a Thermo Fisher deal collapsed
Qiagen's boards will recommend EQT's all-cash offer of €46.50 a share, which values the company at about €10.8 billion, or roughly $12.1 billion, including net debt. Closing is expected in mid-2027.

- Value
- €10.8B
- Type
- Acquisition
- Target
- Qiagen
- Buyer
- EQT Private Equity
- Sector
- Diagnostics
- Announced
- Oct. 21, 2026
Qiagen has agreed to a sale again. The diagnostics and life science tools company said Oct. 21 that its boards will recommend an all-cash takeover offer of €46.50 a share from EQT Private Equity, a deal that values Qiagen at about €10.8 billion including net debt.
Qiagen put that at roughly $12.1 billion at current exchange rates, including about $1.1 billion of net debt. The offer is a 40.3% premium to Qiagen's Xetra closing price of €33.15 on July 8, the final trading day before reports emerged of private equity interest, and a 46.9% premium to the three-month volume-weighted average price up to that date.
Why it matters: The offer puts Qiagen's shareholders to a price test for a second time. Six years ago, a planned sale to Thermo Fisher Scientific collapsed when shareholders balked at the price, MedTech Dive noted. This time, William Blair analysts said the price works out to about 15 times their estimate of Qiagen's 2027 earnings before interest, taxes, depreciation and amortization, below the high teens to low 20s they said is typical for comparable life sciences deals.
The analysts called the offer reasonable in light of Qiagen's comparatively slower growth, writing that "broader-based growth has remained elusive," according to MedTech Dive.
The offer arrives less than a week after another diagnostics deal, Labcorp's agreement to buy BioReference testing assets from Opko Health for $722 million upfront.
The offer will come from Crown NL Bidco, a holding company that the EQT XI fund controls indirectly. Two co-investors hold indirect stakes: Luxinva, a subsidiary of the Abu Dhabi Investment Authority, and CPP Investment Board Europe, a subsidiary of Canada Pension Plan Investment Board.
EQT said it manages 354 billion euros in assets and has invested more than 30 billion euros in more than 210 healthcare companies. Its current and former holdings include Galderma, Parexel, Aldevron, Dako and HemoCue, according to the release. EQT agreed to commitments covering Qiagen's strategy, key brands, operational footprint, research and development and employees, and the company will keep the Qiagen name.
Qiagen said the agreement came out of a strategic review that included talks with industry buyers as well as financial investors. The deal came less than two months after Qiagen installed Jonathan M. Pratt as chief executive, MedTech Dive reported.
"Under private ownership, we can move faster and have greater freedom to put resources behind the most attractive opportunities," Pratt said.
How the offer works
Qiagen's supervisory board and managing board unanimously support the deal. The offer needs acceptances from holders of 50% of Qiagen's outstanding shares plus one share, shareholder approval at an extraordinary general meeting of steps to complete the takeover after closing, and antitrust and foreign investment approvals. EQT has lined up equity and debt commitments, and the offer has no financing condition.
The boards will move ahead with those post-closing steps if 80% or more of votes cast at the meeting approve them, the release says. Below that level, the boards may still proceed if they determine that doing so is in Qiagen's best interest and is backed by a substantial majority of shareholders. Shareholders who do not tender would receive a cash distribution equal to the offer price minus withholding taxes, which could leave them with less than tendering would.
If regulatory approvals are still pending 10 months after the announcement, Qiagen may pay an interim dividend of up to $0.47 a share that would not reduce the offer price.
Moelis & Company and Goldman Sachs Bank Europe are Qiagen's financial advisers. Morgan Stanley and Jefferies are lead financial advisers to EQT, with Milbank as lead legal counsel.
What comes next
Germany's financial regulator, BaFin, must approve the offer document before the acceptance period can begin, and the bidder will then launch the offer in the U.S. with a Schedule TO filing at the Securities and Exchange Commission. The companies expect to close in mid-2027. After that, Qiagen's shares would stop trading on the Frankfurt Stock Exchange and the New York Stock Exchange.



